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The Mosaic of Coronavirus Vaccine
Development: Systemic Failures in
Vaccine Innovation
Scientists are racing to develop vaccines against the novel coronavirus.
While some vaccine candidates may enter the market in record time, the
current vaccine innovation ecosystem exposes governance lacunas at both
the international and domestic levels.
Scientists across the globe have been racing to develop vaccines against the
novel coronavirus since its outbreak in early 2020. Following a period of
lukewarm interest from the private sector, dozens of companies and
universities quickly entered into vaccine development partnerships.
The most advanced vaccine candidates emerging from these partnerships
started being tested on human subjects just a few weeks after initial research
and development (R&D). This is a remarkably expedited timeline compared to
the multi-year timeline usually needed to fully develop and produce a vaccine
for testing.
In the United States, a vaccine developed by the National Institute of Allergy
and Infectious Diseases in conjunction with an American biotech company,
Moderna, began a six-week clinical trial in Seattle on March 16. Two days later,
CanSino Biologics, a Chinese company, announced that its vaccine candidate,
developed in partnership with the Chinese Academy of Military Medical
Sciences, had also been cleared for human trials. That same week, a small
German biotech company, CureVac, received 80 million euros from the
European Commission to bring a vaccine candidate into clinical trials by early
summer. Another German company, BioNTech, entered into a partnership with
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Pfizer to initiate clinical trials in April.
The quick-assembling mosaic of coronavirus vaccine development projects
speaks to the propulsive effects of global health crises on vaccine R&D. At the
same time, however, it sheds light on the systemic shortcomings affecting
vaccine development targeting emerging pathogens.
First, investment in vaccine R&D remains unattractive to private-sector
companies. Large pharmaceutical companies with the infrastructure
necessary to produce massive amounts of vaccines tend to allocate resources
elsewhere, as vaccine manufacturing is widely deemed unprofitable. Second,
outbreak-spiked funding for vaccine development is likely to decline
precipitously as soon as the pandemic begins to wane, cutting short many of
the development projects now underway, as was the case in the recent
outbreaks of Ebola and Zika. And third, for the vaccines that are fully
developed, there is no guarantee that they will be made available at affordable
prices to all populations in need.
While some of these problems stem from the fact that the preventative nature
of vaccines makes them less commercially appealing than drugs or treatments
addressing mainstream diseases, others are the product of policy choices and
legal infrastructure.
These problems relate partly to governance deficits in biopharmaceutical
innovation systems. Even amidst public health crises, the process of
developing cost-effective tools to prevent or curb outbreaks remains scattered
among a multitude of players. While there are several transnational actors
involved in global vaccine policy, there is no single institution or institutional
network, focused primarily on the innovation dynamics surrounding vaccine
development.
The World Health Organization (WHO), which oversees a large number of
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vaccine-related areas, ranging from support and coordination of clinical trials,
to providing guidance on immunization best practices and on vaccine policy, is
not in a position to shift its attention and resources to address investment and
market-related issues.
Over the past two decades, the primary mechanism to address problems
surrounding the development and deployment of new vaccines has been
through the formation of transnational public-private partnerships. Unlike the
WHO and other global health actors, these partnerships operate exclusively in
the area of vaccines. For instance, Gavi, a Geneva-based international
organization, focuses on expanding access to vaccines in lower-income
countries, thereby indirectly increasing demand for vaccine products. In the
wake of the 2014 to 2016 Ebola outbreak, the Coalition for Epidemic
Preparedness Innovations (CEPI) was created to fund and coordinate the
development of vaccines targeting infectious diseases.
While the creation of CEPI constitutes a direct response to both shortcomings
in the field of incentives to vaccine R&D and to coordination problems, it is
unlikely to be enough. Although transnational public-private partnerships in
the health space have been proliferating since the turn of the century, they
face several challenges. These include resource limitations, funding shortages,
shifting transaction costs, and internal power asymmetries.
The problems created by resource scarcity at the beginning of the vaccine
R&D pipeline are further compounded by problems arising at the end of the
pipeline. Even in the case of vaccines that attract sufficient funding and are
clinically successful, pricing and other intellectual property-related issues may
arise during a vaccineʼs commercialization, rendering it unaffordable to large
swaths of indicated populations.
Many components needed to develop new vaccines are patented. Absent a
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specific commitment to affordable pricing practices, the law gives companies
holding rights over these vaccines the ability to prevent competitors from
entering the market and thus charge supra-competitive prices. Even when
legal frameworks require funders and patent holders to follow rules designed
to increase competition and keep prices in check, these provisions often fail to
be enforced. For instance, during the Zika outbreak, the U.S. Army declined to
negotiate affordable pricing provisions with the manufacturer of the leading
Zika vaccine candidate, citing, among other factors, its lack of expertise in this
type of negotiation.
This problem stems from a globalized intellectual property framework, which
has been implemented at the national level in ways that increase the rights of
patent holders, but do not balance these rights with appropriate access and
pricing provisions. International intellectual property treaties impose a balance
between rights and obligations, particularly where health technologies are
concerned. National applications of the international frameworks, however,
routinely fall short of presenting a meaningful interpretation to balancing
provisions, such as ensuring life-saving technologies like vaccines are not
overpriced.
The case of the current coronavirus vaccines under development illustrates
this point. On February 27, as the magnitude of the outbreak was becoming
apparent, Secretary of U.S. Health and Human Services Alex Azar stated the
government could not promise that the resulting vaccines would be sold at
affordable prices.
Yet, nothing in international intellectual property frameworks prevents
governments from taking such steps. In mid-March, Chile used an
international law mechanism to pass a resolution allowing the government to
issue compulsory licenses for any products needed to fight the coronavirus
pandemic, including vaccines.
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As outbreaks of infectious diseases are predicted to occur more frequently in
our globalized world, this dissociation between the public health value of
vaccines and the institutional and legal infrastructure supporting vaccine
development and commercialization is increasingly problematic. Creating
dedicated public-private partnerships is a step in the right direction to address
the problem of insufficient funding for vaccine development. But if countries
are unwilling to explore the full range of legal and policy tools available to make
vaccines affordable, many populations across the globe will be deprived of
access to critical public health tools.
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